We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Syndexa Pharmaceuticals Secures Investment by MP Healthcare Venture Management
News

Syndexa Pharmaceuticals Secures Investment by MP Healthcare Venture Management

Syndexa Pharmaceuticals Secures Investment by MP Healthcare Venture Management
News

Syndexa Pharmaceuticals Secures Investment by MP Healthcare Venture Management

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Syndexa Pharmaceuticals Secures Investment by MP Healthcare Venture Management"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

In conjunction with the Series B1 transaction, Tetsuro Iwata will represent MPH as an Observer on Syndexa's Board of Directors.

"This funding from new investor, MP Healthcare Venture Management, and support from Tetsuro Iwata comes at an important time for Syndexa," said Teo Uysal, President and CEO. "The proceeds from our Series B1 will enable us to progress the preclinical development of our Endoplasmic Reticulum (ER) modulating compounds towards development candidate selection, and will allow us to validate the therapeutic potential of our most promising compounds in various indications of ER dysfunction."

Advertisement